Highlights Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - OTC Markets Other stock markets 21:00:00 07/05/2024 BST			5-day change	1st Jan Change
10.94 ^USD	+4.29%		+7.36%	-2.32%

04-11	Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	MT
03-22	B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Decliners	03-20	MT
Harrow, Inc. Provides Earnings Guidance for the Year 2024	03-20	CI
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	03-20	MT
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19	CI
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Restore stock falls as weak tech trading drags down annual results	03-14	AN
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	01-11	CI
Harrow, Inc. Partners with Leading Healthcare Market Access Technology Platforms	01-03	CI
Harrow Collaborating With Three Health Technology Platforms for US Launch of Vevye	01-03	MT
Harrow, Inc. Completes Transfer of the TRIESENCE New Drug Application	11-29	CI
Inflation Data Awaited as Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Tuesday	11-14	MT
Harrow Health Q3 Core Loss Widens, Revenue Rises; Shares Plunge After Hours	11-13	MT
Harrow, Inc. Revises Revenue Guidance for the Full Year 2023	11-13	CI
Harrow, Inc. Provides Revenue Guidance for the First Quarter and Full Year 2024	11-13	CI
Harrow, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Harrow, Inc. Completes Transfer of Ndas and Launches FLAREX, Natacyn St, Verkazia, and ZERVIATE in the U.S	24/10/23	CI
Harrow Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Harrow Launches VIGAMOX in the U.S	31/07/23	CI
Bank Earnings Leave Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday	19/07/23	MT
Harrow Health Acquires Certain US, Canada Rights to Santen Pharmaceutical's Ophthalmic Portfolio	19/07/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Harrow, Inc.

Equities

HROW

US4158581094

Highlights

Filters